NASDAQ:CNMD - CONMED Stock Price, News, & Analysis

CONMED trades on the NASDAQ under the ticker symbol "CNMD."

CONMED declared a quarterly dividend on Tuesday, August 14th. Stockholders of record on Friday, September 14th will be given a dividend of $0.20 per share on Monday, October 8th. This represents a $0.80 annualized dividend and a dividend yield of 1.02%. The ex-dividend date of this dividend is Thursday, September 13th. View CONMED's Dividend History.

CONMED Co. (NASDAQ:CNMD) released its quarterly earnings results on Wednesday, August, 1st. The medical technology company reported $0.46 earnings per share for the quarter, beating the Zacks' consensus estimate of $0.45 by $0.01. The medical technology company had revenue of $212.80 million for the quarter, compared to analysts' expectations of $207.12 million. CONMED had a net margin of 8.85% and a return on equity of 9.51%. CONMED's revenue for the quarter was up 7.9% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.41 EPS. View CONMED's Earnings History.

CONMED is scheduled to release their next quarterly earnings announcement on Thursday, November, 1st 2018. View Earnings Estimates for CONMED.

CONMED updated its FY18 earnings guidance on Wednesday, August, 1st. The company provided earnings per share (EPS) guidance of $2.15-2.20 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.17.

3 brokers have issued twelve-month price objectives for CONMED's shares. Their forecasts range from $46.00 to $83.00. On average, they expect CONMED's stock price to reach $64.50 in the next year. This suggests that the stock has a possible downside of 17.6%. View Analyst Price Targets for CONMED.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CONMED in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for CONMED.

Some companies that are related to CONMED include LivaNova (LIVN), Masimo (MASI), GETINGE AB/ADR (GNGBY), NxStage Medical (NXTM), AxoGen, Inc Common Stock (AXGN), Natus Medical (BABY), Viewray (VRAY), Cutera (CUTR), electroCore (ECOR), BioLife Solutions (BLFS), Rockwell Medical (RMTI), Vision Sciences (CGNT), Helius Medical Technologies (HSDT), Fonar (FONR) and Semler Scientific (SMLR).

Media stories about CNMD stock have been trending somewhat negative recently, Accern Sentiment Analysis reports. The research group identifies positive and negative media coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. CONMED earned a coverage optimism score of -0.04 on Accern's scale. They also gave press coverage about the medical technology company an impact score of 48.37 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future. View Recent Headlines for CONMED.

CONMED's stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (13.37%), Dimensional Fund Advisors LP (6.70%), SCOPIA CAPITAL MANAGEMENT LP (6.60%), Scopia Capital Management LP (6.13%), Victory Capital Management Inc. (4.32%) and Macquarie Group Ltd. (2.77%). Company insiders that own CONMED stock include Charles Farkas, Curt R Hartman, Daniel Jonas, Dirk Kuyper, Heather L Cohen, Jo Ann Golden, Luke A Pomilio, Mark E Tryniski, Nathan Folkert and Terence M Berge. View Institutional Ownership Trends for CONMED.

CNMD stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Scopia Capital Management LP, Dimensional Fund Advisors LP, Epoch Investment Partners Inc., WINTON GROUP Ltd, Millennium Management LLC, United Services Automobile Association and Huber Capital Management LLC. Company insiders that have sold CONMED company stock in the last year include Daniel Jonas, Jo Ann Golden, Luke A Pomilio, Nathan Folkert and Terence M Berge. View Insider Buying and Selling for CONMED.

CNMD stock was acquired by a variety of institutional investors in the last quarter, including Hood River Capital Management LLC, FMR LLC, BlackRock Inc., Citadel Advisors LLC, American Century Companies Inc., Granahan Investment Management Inc. MA, Bank of Montreal Can and First Trust Advisors LP. Company insiders that have bought CONMED stock in the last two years include Charles Farkas, Curt R Hartman, Heather L Cohen and Mark E Tryniski. View Insider Buying and Selling for CONMED.

Shares of CNMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of CNMD stock can currently be purchased for approximately $78.26.

CONMED has a market capitalization of $2.15 billion and generates $796.39 million in revenue each year. The medical technology company earns $55.48 million in net income (profit) each year or $1.89 on an earnings per share basis. CONMED employs 3,100 workers across the globe.

CONMED's mailing address is 525 FRENCH ROAD, UTICA NY, 13502. The medical technology company can be reached via phone at 315-624-3215.